Curis, Inc. (CRIS) Stock Price Down 5.4%
Curis, Inc. (NASDAQ:CRIS)’s share price was down 5.4% during mid-day trading on Monday . The stock traded as low as $0.88 and last traded at $0.88. Approximately 2,101,400 shares changed hands during mid-day trading, an increase of 210% from the average daily volume of 677,276 shares. The stock had previously closed at $0.93.
Several equities analysts have recently issued reports on CRIS shares. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Guggenheim started coverage on Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price objective for the company. BidaskClub cut Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $6.50.
The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.
Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The business had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. During the same period last year, the business posted ($0.21) EPS. Curis’s revenue was up 38.6% on a year-over-year basis. equities research analysts forecast that Curis, Inc. will post -0.41 EPS for the current fiscal year.
In other Curis news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average price of $1.06 per share, with a total value of $53,000.00. Following the transaction, the chief executive officer now owns 115,890 shares of the company’s stock, valued at $122,843.40. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 4.07% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRIS. Prudential Financial Inc. acquired a new position in Curis during the first quarter worth approximately $105,000. American International Group Inc. increased its position in Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after buying an additional 4,560 shares during the period. Vanguard Group Inc. increased its position in Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after buying an additional 304,268 shares during the period. Geode Capital Management LLC increased its position in Curis by 8.3% during the first quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock worth $2,553,000 after buying an additional 70,139 shares during the period. Finally, Bank of America Corp DE increased its position in Curis by 58.7% during the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the period. 46.88% of the stock is currently owned by institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.